Publications database

The use of established prognostic markers has improved the diagnostic stratification and therapeutic approaches of breast cancer. Ubiquitin-like modifier activating enzyme 1 (UBA1), a key enzyme in the ubiquitin-proteasome pathway, has been reported to play a role in the pathogenesis of various malignant tumors. [...]

Venous and arterial thromboembolic events (TEEs) represent a substantial threat for melanoma patients treated with immune checkpoint inhibition (ICI) and have a significant impact on quality of life, therapy outcome, and survival. Existing risk assessment models for predicting TEE risk have been developed for other patient collectives and show poor performance in melanoma patients treated with ICI. [...]

Advanced germ cell tumors (GCT) with bulky retroperitoneal lymph node metastases (>= 5 cm, clinical stage [CS] IIC) or distant metastases (CS III) remain among the solid tumors with the highest cure rates despite an unfavorable prognosis. Pulmonary metastases are associated with better outcomes, whereas non-pulmonary visceral involvement indicates a poorer prognosis. [...]

Recent advancements in data science and robotic surgery have introduced significant opportunities and challenges in the field of healthcare. To assess their implications, a multidisciplinary panel of experts in medicine and computer science convened to evaluate the potential benefits, risks, and ethical considerations associated with these technologies. [...]

The assessment of estrogen/progesterone receptors (ER/PR) and human epidermal growth factor receptor 2 (HER2) is essential for managing breast cancer (BC) patients, as these biomarkers guide targeted therapies. Traditional methods such as immunohistochemistry (IHC) and in situ hybridisation (ISH) are widely used, but they are resource-intensive and time-consuming. [...]

The phase II GeparNuevo trial investigated whether adding durvalumab to neoadjuvant chemotherapy (NACT) only in patients with early triple-negative breast cancer cT1b-cT4a-d would improve pathologic complete response (pCR) rate and patient survival. Hundred and seventy-four patients were randomly assigned to receive durvalumab or placebo concurrently with nab-paclitaxel once per week and followed by dose-dense epirubicin and cyclophosphamide. [...]

We previously conducted the TONE study (Treatment of optic neuritis with erythropoietin, NCT01962571), which analysed 103 patients with acute optic neuritis and no prior history of multiple sclerosis after randomization to receive high-dose erythropoietin or placebo as an adjunct to methylprednisolone pulse therapy. All visual system-related outcomes yielded negative results. [...]